Teva withdraws Shield patent oppositions

Israeli generics company Teva has withdrawn its oppositions to two patents owned by Shield Therapeutics before the European Patent Office (EPO).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Celgene, Teva execs grilled over price hikes

1 October 2020 A US House of Representatives committee has accused Teva and Celgene of imposing unjustified price hikes on blockbuster drugs Copaxone and Revlimid.

Europe

Teva loses TM appeal over ‘French version’ of slogan

9 July 2020 Drug company Teva has lost an appeal over its bid to trademark two word signs, after the tenth chamber of the EU General Court ruled in favour of the European Union IP Office (EUIPO) yesterday, July 8.

More on this story

Americas

Celgene, Teva execs grilled over price hikes

1 October 2020 A US House of Representatives committee has accused Teva and Celgene of imposing unjustified price hikes on blockbuster drugs Copaxone and Revlimid.

Europe

Teva loses TM appeal over ‘French version’ of slogan

More on this story

Americas

Celgene, Teva execs grilled over price hikes

1 October 2020 A US House of Representatives committee has accused Teva and Celgene of imposing unjustified price hikes on blockbuster drugs Copaxone and Revlimid.

Europe

Teva loses TM appeal over ‘French version’ of slogan